Literature DB >> 7761208

Surfactant replacement in neonates with early chronic lung disease.

P B Pandit1, M S Dunn, E N Kelly, M Perlman.   

Abstract

OBJECTIVE: To study the effect of a single dose of exogenous bovine surfactant on oxygen and ventilatory requirements of neonates with early chronic lung disease. STUDY
DESIGN: Prospective pilot study.
SETTING: Three regional neonatal intensive care units.
METHODS: Infants 7 to 30 days old with birth weights less than 1500 g were eligible if they required a fraction of inspired oxygen (FIO2) of more than 0.4, had stable ventilatory requirements for 24 hours before study entry, and showed diffuse haziness on chest radiographs. Those with patent ductus arteriosus or active infection or those receiving steroid therapy were excluded. After treatment with the surfactant, differences in FIO2 and the ventilator efficiency index were analyzed using the Wilcoxon signed rank test.
RESULTS: Ten patients were recruited. Median values (range): birth weight, 693 g (530 to 1100 g); gestation, 25 weeks (24 to 27 weeks); and postnatal age at study entry, 13 days (9 to 30 days). The FIO2 decreased significantly between 0 and 1 hour after surfactant administration, from a median (range) of 0.67 (0.47 to 0.88) to 0.39 (0.28 to 0.63). This effect was sustained for 24 hours (median FIO2, 0.36). Although the FIO2 subsequently increased to 0.49 (range, 0.35 to 0.88) at 72 hours, it was significantly lower than that entry before the study. There was a trend toward an increase in the ventilator efficiency index at 24 and 48 hours.
CONCLUSIONS: A single dose of surfactant is effective in reducing oxygen requirements in neonates with early chronic lung disease. Surfactant replacement may be useful adjunctive therapy in these neonates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7761208

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  New targets for surfactant replacement therapy: experimental and clinical aspects.

Authors:  B Robertson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

3.  Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome.

Authors:  Paola E Cogo; Maddalena Facco; Manuela Simonato; Daniele De Luca; Francesca De Terlizi; Umberto Rizzotti; Giovanna Verlato; Maria Paola Bellagamba; Virgilio P Carnielli
Journal:  Intensive Care Med       Date:  2010-12-10       Impact factor: 17.440

4.  Treatment of severe meconium aspiration syndrome with porcine surfactant. Collaborative Surfactant Study Group.

Authors:  H L Halliday; C P Speer; B Robertson
Journal:  Eur J Pediatr       Date:  1996-12       Impact factor: 3.183

Review 5.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

Review 6.  Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future?

Authors:  Emmanuel Lopez; Géraldine Gascoin; Cyril Flamant; Mona Merhi; Pierre Tourneux; Olivier Baud
Journal:  BMC Pediatr       Date:  2013-10-10       Impact factor: 2.125

Review 7.  Surfactants: past, present and future.

Authors:  H L Halliday
Journal:  J Perinatol       Date:  2008-05       Impact factor: 2.521

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.